Clinical Trial Update: A Randomized, Double-blind, Placebo-controlled Clinical Study of the Oral IL-12/23 Inhibitor, STA-5326 Mesylate, Administered to Patients With Rheumatoid Arthritis to Determine Safety, Tolerability, Pharmacokinetic and Synovial Tissue Outcomes [Phase 2]

View source ↗

Summary

A Phase 2 randomized, double-blind, placebo-controlled trial evaluating the oral IL-12/23 inhibitor STA-5326 Mesylate in active rheumatoid arthritis has complet…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• STA-5326 Mesylate (STA-5326 mesylate)

Snippet

Sponsor: Synta Pharmaceuticals Corp. | Conditions: Active, Moderate to Severe Rheumatoid Arthritis | Phase 2 | Status: COMPLETED